Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BM41 in birch pollen allergy
NCT04912076Phase 1Completed
- Sponsor
- University Hospital Odense
- Start
- Sep 2018
- Primary completion
- Mar 2019
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of BM41 in birch pollen allergy and allergic rhinoconjunctivitis (ARC), sponsored by University Hospital Odense. Started Sep 2018; status: completed.
02
Drugs
BM41
03
Conditions
birch pollen allergyallergic rhinoconjunctivitis (ARC)
Beyond the preview
Go deeper on NCT04912076.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04912076.